SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-20-008400
Filing Date
2020-12-07
Accepted
2020-12-07 08:00:29
Documents
15
Period of Report
2020-12-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_120620.htm   iXBRL 8-K 16003
2 EXHIBIT 99.1 exh_991.htm EX-99.1 19527
3 EXHIBIT 99.2 exh_992.htm EX-99.2 19450
  Complete submission text file 0001171843-20-008400.txt   276454

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3095
5 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25969
6 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 35566
7 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 24600
8 EXTRACTED XBRL INSTANCE DOCUMENT f8k_120620_htm.xml XML 3061
Mailing Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Business Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Filer) CIK: 0001629137 (see all company filings)

IRS No.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37539 | Film No.: 201371375
SIC: 2834 Pharmaceutical Preparations